The subsequent randomized phase 3 EMBRACA trial in patients with BRCA1/2-mutated advanced breast cancer showed an improvement compared to standard therapy in progression-free survival (PFS) (8.6 vs. 5.6 months) [26]. Here, BRCA1 is linked to breast carcinoma.